KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Vertex Pharmaceuticals (VRTX) over the last 14 years, with Q3 2025 value amounting to -$9.8 million.

  • Vertex Pharmaceuticals' Other Non Operating Income rose 4201.18% to -$9.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.1 million, marking a year-over-year increase of 6407.41%. This contributed to the annual value of -$86.1 million for FY2024, which is 27763.16% down from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Other Non Operating Income of -$9.8 million as of Q3 2025, which was up 4201.18% from $13.2 million recorded in Q2 2025.
  • Vertex Pharmaceuticals' 5-year Other Non Operating Income high stood at $42.4 million for Q3 2021, and its period low was -$78.1 million during Q2 2022.
  • Moreover, its 5-year median value for Other Non Operating Income was -$14.9 million (2024), whereas its average is -$14.9 million.
  • In the last 5 years, Vertex Pharmaceuticals' Other Non Operating Income tumbled by 250000.0% in 2024 and then surged by 15714.29% in 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Other Non Operating Income (Quarter) stood at $7.1 million in 2021, then tumbled by 538.03% to -$31.1 million in 2022, then surged by 68.49% to -$9.8 million in 2023, then crashed by 52.04% to -$14.9 million in 2024, then soared by 34.23% to -$9.8 million in 2025.
  • Its Other Non Operating Income stands at -$9.8 million for Q3 2025, versus $13.2 million for Q2 2025 and -$17.6 million for Q1 2025.